The Library
Economic evaluation of nebulized magnesium sulphate in acute severe asthma in children
Tools
Petrou, Stavros, Boland, Angela, Khan, Kamran, Powell, Colin, Kolamunnage-Dona, Ruwanthi, Lowe, John, Doull, Iolo, Hood, Kerry and Williamson, P. R. (Paula R.) (2014) Economic evaluation of nebulized magnesium sulphate in acute severe asthma in children. International Journal of Technology Assessment in Health Care, 30 (4). pp. 354-360. doi:10.1017/S0266462314000440 ISSN 0266-4623.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1017/S0266462314000440
Abstract
Objectives: The aim of this study was to estimate the cost-effectiveness of nebulized magnesium sulphate (MgSO4) in acute asthma in children from the perspective of the UK National Health Service and personal social services.
Methods: An economic evaluation was conducted based on evidence from a randomized placebo controlled multi-center trial of nebulized MgSO4 in severe acute asthma in children. Participants comprised 508 children aged 2–16 years presenting to an emergency department or a children's assessment unit with severe acute asthma across thirty hospitals in the United Kingdom. Children were randomly allocated to receive nebulized salbutamol and ipratropium bromide mixed with either 2.5 ml of isotonic MgSO4 or 2.5 ml of isotonic saline on three occasions at 20-min intervals. Cost-effectiveness outcomes were constructed around the Yung Asthma Severity Score (ASS) after 60 min of treatment; whilst cost-utility outcomes were constructed around the quality-adjusted life-year (QALY) metric. The nonparametric bootstrap method was used to present cost-effectiveness acceptability curves at alternative cost-effectiveness thresholds for either: (i) a unit reduction in ASS; or (ii) an additional QALY.
Results: MgSO4 had a 75.1 percent probability of being cost-effective at a GBP 1,000 (EUR 1,148) per unit decrement in ASS threshold, an 88.0 percent probability of being more effective (in terms of reducing the ASS) and a 36.6 percent probability of being less costly. MgSO4 also had a 67.6 percent probability of being cost-effective at a GBP 20,000 (EUR 22,957) per QALY gained threshold, an 8.5 percent probability of being more effective (in terms of generating increased QALYs) and a 69.1 percent probability of being less costly. Sensitivity analyses showed that the results of the economic evaluation were particularly sensitive to the methods used for QALY estimation.
Conclusions: The probability of cost-effectiveness of nebulized isotonic MgSO4, given as an adjuvant to standard treatment of severe acute asthma in children, is less than 70 percent across accepted cost-effectiveness thresholds for an additional QALY.
Item Type: | Journal Article | ||||||
---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RJ Pediatrics | ||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
Library of Congress Subject Headings (LCSH): | Asthma in children, Asthma in children -- Treatment -- Evaluation, Magnesium sulfate -- Therapeutic use -- Evaluation, Clinical trials | ||||||
Journal or Publication Title: | International Journal of Technology Assessment in Health Care | ||||||
Publisher: | Cambridge University Press | ||||||
ISSN: | 0266-4623 | ||||||
Official Date: | October 2014 | ||||||
Dates: |
|
||||||
Volume: | 30 | ||||||
Number: | 4 | ||||||
Page Range: | pp. 354-360 | ||||||
DOI: | 10.1017/S0266462314000440 | ||||||
Status: | Peer Reviewed | ||||||
Publication Status: | Published | ||||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |